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Letter to the Editor
I enjoyed reading the paper entitled “Clinical and hemato-
logical manifestations of visceral leishmaniasis in Yemeni chil-
dren” by Hamid and Gobah in the recent issue of the Turkish 
Journal of Hematology [1].
Their documentations in Aden University were similar to our 
findings in 156 children with visceral leishmaniasis (VL) in İhsan 
Doğramacı Children’s Hospital at Hacettepe University in 
Ankara [2,3]. I would like to share our experiences with the 
authors, especially in the prevention and treatment of the dis-
ease. They stated that “It is essential that the Ministry of Public 
Health be more aware of the condition in order to impose envi-
ronmental sanitation and personnel protective measures and 
establish diagnostic laboratories for early and correct diagnosis 
and treatment.” In my observation, this attitude is fairly com-
mon in the developing country universities. Actually, I believe 
the universities should be involved in the country’s problem. 
We initiated a program with the Turkish Ministry of Health 
for the prevention of the disease in an area called Mut, from 
where most of our patients originated. With the active surveil-
lance of our two residents, phlebotome eradication was 
accomplished in a relatively short period of time.
Although liposomal amphotericin B is the most often 
advised treatment for VL currently, our results with meglumine 
antimonate (MA; glucantime), which began with a dose of 20 
mg/kg/day for 3 days, was increased to 30 mg/kg/day for 3 
days and/or then increased to 60 mg/kg per day for 2 weeks, 
for a total of 20 days) followed by pentamidine isethionate (PI) 
every other day for a total 15 doses (2.5 mg/kg/day), gave bet-
ter results, and is much cheaper [4-6], an important factor for 
the developing countries. In general, any treatment should be 
effective, applicable, practical, ethical, economical and ecologi-
cal. Of course the cheapest approach would be the eradication 
of the sandfly, which will prevent the dissemination of VL.
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Author Reply
To the Editor,
 I agree with Professor Özsoylu about awareness of the 
Ministry of Public Health and the universities to improve the 
diagnosis, treatment and prevention of visceral leishmaniasis. 
At this time we are lucky, because the Minster of Public Health 
is a Professor of Pediatrics and was Rector of Aden University. 
During a short period, he initiated strong challenges to activate 
control programs for leishmania, malaria, tuberculosis, bilhar-
ziosis and many other programs, and we thank him for his 
response to our recommendations.
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